A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
Principal Investigator
Donna E. HoggeOverview
Body Locations and Systems
LeukemiaDisorders and Conditions
Health Conditions
Acute Myeloid LeukemiaClinicalTrials.gov#
NCT01191801Status
Closed for RecruitmentStudy Start/End
May 1, 2011 to May 1, 2016Locations
Vancouver General HospitalName/Title
Mabel Ma, Research AssistantPhone
604-537-1433Email Address
mabel.ma@alumni.ubc.caPurpose of Study
This study will compare the overall survival (OS) between treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.